• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by ENDRA Life Sciences Inc.

    10/30/25 9:05:16 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NDRA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    ENDRA Life Sciences Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001

    (Title of Class of Securities)


    29273B302

    (CUSIP Number)


    10/23/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    29273B302


    1Names of Reporting Persons

    John Carter Lipman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    115,477.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    115,477.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    115,477.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  (1) Represents 76,104 shares of the Issuer's Common Stock Purchased by the Reporting Person and, due to a 9.99% beneficial ownership blocker, 39,373 shares of Common Stock issuable upon the exercise of Common Stock purchase warrants exercisable within 60 days. (2) Does not include 112,835 shares of Common Stock issuable upon the exercise of Common Stock purchase warrants, which are subject to a 9.99% beneficial ownership limitation. The numbers in this Schedule 13G do not give effect to the increased number of shares potentially issuable under such Common Stock purchase warrants because the beneficial ownership limitation apply. (3) Based upon 1,166,441 shares of Common Stock issued and outstanding as reported in the Issuer's preliminary Proxy Statement on Schedule 14A filed on October 17, 2025. (4) The Reporting Person has not acquired the securities with any purpose, or with the effect, of changing or influencing the control of the Issuer, or in connection with or as a participant in any transaction having that purpose or effect, including any transaction subject to Rule 13d-3(b).


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ENDRA Life Sciences Inc.
    (b)Address of issuer's principal executive offices:

    3600 Green Court, Suite 350, Ann Arbor, MI 48105
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is filed by John Carter Lipman (hereinafter referred to as the "Reporting Person.")
    (b)Address or principal business office or, if none, residence:

    570 Lexington avenue 40th floor New York, New York 10022
    (c)Citizenship:

    United States of America
    (d)Title of class of securities:

    Common Stock, par value $0.0001
    (e)CUSIP No.:

    29273B302
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Items 4(a)-(c) is set forth in Rows 5-11 of each Cover Page and is incorporated herein by reference. Each Reporting Person expressly declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.
    (b)Percent of class:

    The information required by Items 4(a)-(c) is set forth in Rows 5-11 of each Cover Page and is incorporated herein by reference. Each Reporting Person expressly declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Items 4(a)-(c) is set forth in Rows 5-11 of each Cover Page and is incorporated herein by reference. Each Reporting Person expressly declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     (ii) Shared power to vote or to direct the vote:

    The information required by Items 4(a)-(c) is set forth in Rows 5-11 of each Cover Page and is incorporated herein by reference. Each Reporting Person expressly declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Items 4(a)-(c) is set forth in Rows 5-11 of each Cover Page and is incorporated herein by reference. Each Reporting Person expressly declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Items 4(a)-(c) is set forth in Rows 5-11 of each Cover Page and is incorporated herein by reference. Each Reporting Person expressly declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    John Carter Lipman
     
    Signature:/s/ John Carter Lipman
    Name/Title:John Carter Lipman
    Date:10/30/2025
    Get the next $NDRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NDRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NDRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Market maker/broker-dealer Ubs Group Ag bought 0 shares (SEC Form 4)

    4/A - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    9/5/24 3:28:10 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Large owner Ubs Group Ag bought $2,052 worth of shares (3,715 units at $0.55) (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    8/29/24 4:30:01 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use

    Feasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoring ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermo-acoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced new results from its 2025 TAEUS Liver device feasibility study demonstrating that TAEUS' thermo-acoustic fat fraction (TAFF) measurement closely tracks the MRI-PDFF gold standard at critical liver fat fraction (LFF) thresholds of 12-17% and 20-22%. These thresholds separate mild, moderate and severe disease, are widely

    12/4/25 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker

    TAEUS Liver demonstrates strong agreement with the industry's imaging gold standard, MRI‑PDFF, across the full spectrum of steatotic liver disease and patient BMI ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction-associated liver disease ("MASLD") and metabolic dysfunction-associated steatohepatitis ("MASH"), today announces encouraging preliminary results from a single-site clinical feasibility study evaluating its improved TAEUS Liver device for quantifying liver fat fraction, which is a key biomarker of steatotic liver disease ("SLD"). The preliminary study res

    11/20/25 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results

    ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease ("MASLD") and metabolic dysfunction associated steatohepatitis ("MASH"), today provided a business update and reported financial results for the three and nine months ended September 30, 2025. Business Update Completed private placement of up to $14.4 million. On October 23, 2025, the Company closed a private investment in public equity (PIPE) financing led by institutional investors. The PIPE generated gross proceeds of approximately $4.9 million before placement agent fees and expenses,

    11/17/25 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Digiandomenico Anthony was granted 70,822 shares, increasing direct ownership by 1,301% to 76,265 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    10/15/25 9:54:17 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Basenese Lou was granted 5,384 shares, increasing direct ownership by 538,400% to 5,385 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    7/1/25 6:26:33 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Harsh Michael was granted 5,384 shares, increasing direct ownership by 269,200% to 5,386 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    7/1/25 6:25:48 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    SEC Filings

    View All

    ENDRA Life Sciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)

    11/28/25 4:23:04 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SCHEDULE 13D filed by ENDRA Life Sciences Inc.

    SCHEDULE 13D - ENDRA Life Sciences Inc. (0001681682) (Subject)

    11/26/25 4:30:31 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B4 filed by ENDRA Life Sciences Inc.

    424B4 - ENDRA Life Sciences Inc. (0001681682) (Filer)

    11/26/25 8:30:32 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    Leadership Updates

    Live Leadership Updates

    View All

    ENDRA Life Sciences Appoints Irina Pestrikova as Senior Director of Finance, Announces Departure of CFO David Wells

    ANN ARBOR, MI / ACCESSWIRE / June 15, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced the appointment of Irina Pestrikova as Senior Director of Finance and Principal Financial Officer. In this new position, Ms. Pestrikova will assume all day-to-day responsibilities previously performed by ENDRA's Chief Financial Officer David Wells, who will leave the Company effective June 18, 2021 to pursue another opportunity.Ms. Pestrikova has supported ENDRA since 2014 and has been actively involved in ENDRA's financial planning and analysis, accounting and SEC reporting functions. Previously, Ms. Pestrikova was a financial analyst at a

    6/15/21 8:35:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ENDRA Life Sciences Inc.

    SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

    6/14/24 4:01:26 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by ENDRA Life Sciences Inc.

    SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

    6/14/24 8:00:02 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by ENDRA Life Sciences Inc.

    SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

    3/10/23 12:18:14 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    Financials

    Live finance-specific insights

    View All

    ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

    ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update. Business Update ENDRA made significant progress against many of the new initiatives discussed during the Company's August 22, 2024, conference call to advance its TAEUS Liver device along the development and regulatory process. In addition, ENDRA separately announced today a revamped strategy for TAEUS as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs. ENDRA's prog

    3/31/25 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

    ENDRA Life Sciences Inc. (NASDAQ:NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it has regained compliance with the minimum bid price requirement set forth by The Nasdaq Stock Market LLC ("Nasdaq"). On November 21, 2024, the Company received notification from the Nasdaq Listing Qualifications Department confirming its compliance with Listing Rule 5550(a)(2), thereby meeting Nasdaq's maintenance requirements for listing. "Now that we have regained compliance with Nasdaq's listing requirements, we can focus all our efforts on making progress on our new transformational business strategies, which we reviewed during our August 22nd conference call,

    11/22/24 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

    ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it will host a conference call and webcast beginning at 4:30 p.m. Eastern time on August 22, 2024, to discuss quarterly results, provide an update on recent corporate developments and answer questions. This call was previously scheduled for August 14, 2024. The Company will file its quarterly report on form 10-Q with the SEC as regularly scheduled in the coming days. A press release summarizing its financial and operating results for the second quarter ending on June 30, 2024, will be issued on the day of the call. Participants are encouraged to pre-register

    8/13/24 4:05:00 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care